{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1364233268672003456.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1440-1746.2008.05593.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2008.05593.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1746.2008.05593.x"}},{"identifier":{"@type":"PMID","@value":"19215336"}}],"dc:title":[{"@value":"Efficacy and safety of entecavir in nucleoside‐naive, chronic hepatitis B patients: Phase II clinical study in Japan"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aim: </jats:bold> Entecavir has demonstrated clinical efficacy for chronic hepatitis B. This study evaluated the efficacy and safety of entecavir in nucleoside‐naive Japanese chronic hepatitis B patients.</jats:p><jats:p><jats:bold>Methods: </jats:bold> In this multicenter, double‐blind study, 66 nucleoside‐naive Japanese chronic hepatitis B patients were randomized to 0.1 mg entecavir (<jats:italic>n</jats:italic> = 32) or 0.5 mg entecavir (<jats:italic>n</jats:italic> = 34) daily for 52 weeks. The primary endpoint was the proportion of patients whose serum hepatitis B virus (HBV) DNA decreased from baseline by ≥2 log<jats:sub>10</jats:sub> copies/mL or became undetectable (<400 copies/mL by polymerase chain reaction assay) at week 48.</jats:p><jats:p><jats:bold>Results: </jats:bold> One hundred percent of patients in both treatment groups achieved the primary efficacy endpoint, with 81% and 68% of patients achieving undetectable HBV DNA in the 0.1 mg and 0.5 mg treatment groups, respectively. Mean changes from baseline in HBV DNA were −4.49 log<jats:sub>10</jats:sub> and −4.84 log<jats:sub>10</jats:sub> copies/mL for the 0.1 mg and 0.5 mg groups, respectively. Significant improvements in necroinflammation were seen in both groups, as assessed by Knodell and New Inuyama classifications. Most adverse events were transient and classified as grade 1 or 2. There were no clinically significant differences in adverse events across the two treatment groups and no discontinuations due to adverse events in either group.</jats:p><jats:p><jats:bold>Conclusions: </jats:bold> In Japanese nucleoside‐naive patients with chronic hepatitis B, 0.1 mg or 0.5 mg entecavir daily provided excellent efficacy and was well tolerated. The 0.5 mg dose was selected for the treatment of nucleoside‐naive patients.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1384233268672003456","@type":"Researcher","foaf:name":[{"@value":"Haruhiko Kobashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003459","@type":"Researcher","foaf:name":[{"@value":"Kouichi Takaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003329","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Ikeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003460","@type":"Researcher","foaf:name":[{"@value":"Osamu Yokosuka"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003464","@type":"Researcher","foaf:name":[{"@value":"Mitsuhiko Moriyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003462","@type":"Researcher","foaf:name":[{"@value":"Fumio Imazeki"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003463","@type":"Researcher","foaf:name":[{"@value":"Masayoshi Kage"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003461","@type":"Researcher","foaf:name":[{"@value":"Taku Seriu"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003458","@type":"Researcher","foaf:name":[{"@value":"Masao Omata"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003457","@type":"Researcher","foaf:name":[{"@value":"Kousaku Sakaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1384233268672003328","@type":"Researcher","foaf:name":[{"@value":"Yasushi Shiratori"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08159319"},{"@type":"EISSN","@value":"14401746"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology and Hepatology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2009-01-22","prism:volume":"24","prism:number":"2","prism:startingPage":"255","prism:endingPage":"261"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2008.05593.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1746.2008.05593.x"}],"createdAt":"2009-01-22","modifiedAt":"2023-10-15","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Guanine","dc:title":"Guanine"},{"@id":"https://cir.nii.ac.jp/all?q=Time%20Factors","dc:title":"Time Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Viral%20Load","dc:title":"Viral Load"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Severity%20of%20Illness%20Index","dc:title":"Severity of Illness Index"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Asian%20People","dc:title":"Asian People"},{"@id":"https://cir.nii.ac.jp/all?q=Double-Blind%20Method","dc:title":"Double-Blind Method"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Liver","dc:title":"Liver"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Resistance,%20Viral","dc:title":"Drug Resistance, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004232280670208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687334912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long‐term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1440-1746.2008.05593.x"},{"@type":"OPENAIRE","@value":"doi_dedup___::817ae98e00ab4ab9a755f26ced5a56eb"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2009.12.036_references_DOI_DKaYflePFYolAXUqxqL18aur038"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_DKaYflePFYolAXUqxqL18aur038"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00785.x_references_DOI_DKaYflePFYolAXUqxqL18aur038"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_DKaYflePFYolAXUqxqL18aur038"}]}